aspen pharmacare hld - APNHY

APNHY

Close Chg Chg %
5.38 0.17 3.16%

Closed Market

5.55

+0.17 (3.16%)

Volume: 8.71K

Last Updated:

Dec 4, 2025, 11:27 AM EDT

Company Overview: aspen pharmacare hld - APNHY

APNHY Key Data

Open

$5.64

Day Range

5.49 - 5.64

52 Week Range

5.24 - 10.14

Market Cap

$2.45B

Shares Outstanding

444.02M

Public Float

N/A

Beta

0.90

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

N/A

Yield

133.36%

Dividend

$0.07

EX-DIVIDEND DATE

Oct 3, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

1.22K

 

APNHY Performance

1 Week
 
3.16%
 
1 Month
 
0.82%
 
3 Months
 
-6.33%
 
1 Year
 
-45.21%
 
5 Years
 
N/A
 

APNHY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About aspen pharmacare hld - APNHY

Aspen Pharmacare Holdings Ltd. manufactures and supplies branded and generic pharmaceutical products. It operates through the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals segment consists of the following business sub segments: Sterile Focused Brands, which includes the Anaesthetics and Thrombosis portfolios; and Regional Brands, which are products that are managed on a regional basis. The Manufacturing segment focuses on the following business sub segments: Active Pharmaceutical Ingredients, which involved in API Chemicals business and non-heparin biochemical API business; Heparin, which refers to the full value chain contribution from all heparin containing products; FDF Steriles, which includes all FDF sterile sales; and FDF Other, which consists of all non-sterile FDF products. The company was founded by Michael Guy Attridge and Stephen Bradley Saad in 1850 and is headquartered in Durban, South Africa.

APNHY At a Glance

Aspen Pharmacare Holdings Ltd.
Aspen Place, 9 Rydall Vale Park
Durban, KwaZulu-Natal 4019
Phone 27-31-580-8600 Revenue 2.39B
Industry Pharmaceuticals: Major Net Income -59,633,905.01
Sector Health Technology Employees 9,557
Fiscal Year-end 06 / 2026
View SEC Filings

APNHY Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.25
Price to Book Ratio 0.625
Price to Cash Flow Ratio 10.51
Enterprise Value to EBITDA 8.819
Enterprise Value to Sales 1.951
Total Debt to Enterprise Value 0.436

APNHY Efficiency

Revenue/Employee 249,840.32
Income Per Employee -6,239.814
Receivables Turnover 3.031
Total Asset Turnover 0.313

APNHY Liquidity

Current Ratio 2.212
Quick Ratio 1.183
Cash Ratio 0.366

APNHY Profitability

Gross Margin 42.015
Operating Margin 17.30
Pretax Margin -0.284
Net Margin -2.498
Return on Assets -0.781
Return on Equity -1.266
Return on Total Capital -0.876
Return on Invested Capital -0.949

APNHY Capital Structure

Total Debt to Total Equity 42.548
Total Debt to Total Capital 29.848
Total Debt to Total Assets 26.58
Long-Term Debt to Equity 37.115
Long-Term Debt to Total Capital 26.037
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Aspen Pharmacare Hld - APNHY

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
2.54B 2.29B 2.39B 2.39B
Sales Growth
+3.52% -9.69% +4.30% -0.05%
Cost of Goods Sold (COGS) incl D&A
1.38B 1.27B 1.39B 1.38B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
112.54M 100.60M 105.43M 115.03M
Depreciation
76.67M 70.16M 74.28M 80.06M
Amortization of Intangibles
35.87M 30.44M 31.15M 34.97M
COGS Growth
+2.52% -8.34% +9.83% -0.68%
Gross Income
1.15B 1.02B 994.95M 1.00B
Gross Income Growth
+4.75% -11.31% -2.58% +0.83%
Gross Profit Margin
+45.40% +44.59% +41.65% +42.02%
2022 2023 2024 2025 5-year trend
SG&A Expense
545.81M 516.80M 528.28M 590.12M
Research & Development
- - - -
-
Other SG&A
545.81M 516.80M 528.28M 590.12M
SGA Growth
-5.21% -5.31% +2.22% +11.70%
Other Operating Expense
- - - -
-
Unusual Expense
111.82M 60.88M 121.04M 349.98M
EBIT after Unusual Expense
493.98M 443.66M 345.63M 63.10M
Non Operating Income/Expense
82.25M (9.68M) 78.23M 24.23M
Non-Operating Interest Income
6.90M 29.76M 56.59M 19.71M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
41.85M 65.16M 118.52M 94.10M
Interest Expense Growth
-38.03% +55.69% +81.91% -20.60%
Gross Interest Expense
46.05M 67.29M 121.30M 97.74M
Interest Capitalized
4.20M 2.14M 2.78M 3.63M
Pretax Income
534.38M 368.82M 305.34M (6.77M)
Pretax Income Growth
+37.54% -30.98% -17.21% -102.22%
Pretax Margin
+21.07% +16.10% +12.78% -0.28%
Income Tax
108.14M 74.67M 70.00M 52.86M
Income Tax - Current - Domestic
93.68M 95.09M 99.87M 84.85M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
14.45M (20.42M) (29.87M) (31.99M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
426.24M 294.16M 235.34M (59.63M)
Minority Interest Expense
- - - -
-
Net Income
426.24M 294.16M 235.34M (59.63M)
Net Income Growth
+36.94% -30.99% -20.00% -125.34%
Net Margin Growth
+16.81% +12.84% +9.85% -2.50%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
426.24M 294.16M 235.34M (59.63M)
Preferred Dividends
- - - -
-
Net Income Available to Common
426.24M 294.16M 235.34M (59.63M)
EPS (Basic)
0.9409 0.6622 0.5298 -0.1343
EPS (Basic) Growth
+50.16% -29.62% -19.99% -125.35%
Basic Shares Outstanding
453.00M 444.20M 444.20M 444.00M
EPS (Diluted)
0.9409 0.6622 0.5298 -0.1343
EPS (Diluted) Growth
+50.16% -29.62% -19.99% -125.35%
Diluted Shares Outstanding
453.00M 444.20M 444.20M 444.00M
EBITDA
718.34M 605.14M 572.10M 528.12M
EBITDA Growth
+14.06% -15.76% -5.46% -7.69%
EBITDA Margin
+28.32% +26.42% +23.95% +22.12%

Aspen Pharmacare Hld in the News